KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $334.8 million.

  • Acadia Pharmaceuticals' Accumulated Expenses rose 306.99% to $334.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.8 million, marking a year-over-year increase of 306.99%. This contributed to the annual value of $378.7 million for FY2024, which is 5997.48% up from last year.
  • Acadia Pharmaceuticals' Accumulated Expenses amounted to $334.8 million in Q3 2025, which was up 306.99% from $309.9 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Accumulated Expenses high stood at $378.7 million for Q4 2024, and its period low was $80.5 million during Q3 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Accumulated Expenses had a median value of $197.3 million in 2023 and averaged $203.3 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Accumulated Expenses crashed by 892.57% in 2021, and later soared by 10969.4% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Accumulated Expenses (Quarter) stood at $89.2 million in 2021, then rose by 26.56% to $112.9 million in 2022, then skyrocketed by 109.69% to $236.7 million in 2023, then skyrocketed by 59.97% to $378.7 million in 2024, then decreased by 11.58% to $334.8 million in 2025.
  • Its Accumulated Expenses stands at $334.8 million for Q3 2025, versus $309.9 million for Q2 2025 and $284.4 million for Q1 2025.